Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Kevin_Ali
|
| gptkbp:focusesOn |
biosimilars
women's health established brands |
| gptkbp:founded |
2021
|
| gptkbp:headquartersLocation |
gptkb:Jersey_City,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Organon & Co. (2021)
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:S&P_500
|
| gptkbp:notableProduct |
gptkb:Remeron
gptkb:Follistim_AQ gptkb:Ganirelix_Acetate_Injection gptkb:Nexplanon gptkb:Clarinex gptkb:Singulair gptkb:Zetia gptkb:Arcoxia gptkb:Nasonex gptkb:NuvaRing Biosimilar Insulin Glargine Dulera Prolia (biosimilar) |
| gptkbp:numberOfEmployees |
~9,500 (2023)
|
| gptkbp:originatedAsSpinOffFrom |
gptkb:Merck_&_Co.
|
| gptkbp:parentCompanyPriorToSpinOff |
gptkb:Merck_&_Co.
|
| gptkbp:publiclyTraded |
NYSE: OGN
|
| gptkbp:stockExchange |
gptkb:New_York_Stock_Exchange
|
| gptkbp:stockSymbol |
gptkb:OGN
|
| gptkbp:website |
https://www.organon.com/
|
| gptkbp:bfsParent |
gptkb:默沙东
|
| gptkbp:bfsLayer |
5
|